The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Open accessAbstract
The Adult Treatment Panel III (ATP III) of the National Cholesterol Education Program issued an evidence-based set of guidelines on cholesterol management in 2001. Since the publication of ATP III, 5 major clinical trials of statin therapy with clinical end points have been published. These trials addressed issues that were not examined in previous clinical trials of cholesterol-lowering therapy. The present document reviews the results of these recent trials and assesses their implications for cholesterol management. Therapeutic lifestyle changes (TLC) remain an essential modality in clinical management. The trials confirm the benefit of cholesterol-lowering therapy in high-risk patients and support the ATP III treatment goal of low-density lipoprotein cholesterol (LDL-C) <100 mg/dL. They support the inclusion of patients with diabetes in the high-risk category and confirm the benefits of LDL-lowering therapy in these patients. They further confirm that older persons benefit from therapeutic lowering of LDL-C. The major recommendations for modifications to footnote the ATP III treatment algorithm are the following. In high-risk persons, the recommended LDL-C goal is <100 mg/dL, but when risk is very high, an LDL-C goal of <70 mg/dL is a therapeutic option, ie, a reasonable clinical strategy, on the basis of available clinical trial evidence. This therapeutic option extends also to patients at very high risk who have a baseline LDL-C <100 mg/dL. Moreover, when a high-risk patient has high triglycerides or low high-density lipoprotein cholesterol (HDL-C), consideration can be given to combining a fibrate or nicotinic acid with an LDL-lowering drug. For moderately high-risk persons (2+ risk factors and 10-year risk 10% to 20%), the recommended LDL-C goal is <130 mg/dL, but an LDL-C goal <100 mg/dL is a therapeutic option on the basis of recent trial evidence. The latter option extends also to moderately high-risk persons with a baseline LDL-C of 100 to 129 mg/dL. When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, it is advised that intensity of therapy be sufficient to achieve at least a 30% to 40% reduction in LDL-C levels. Moreover, any person at high risk or moderately high risk who has lifestyle-related risk factors (eg, obesity, physical inactivity, elevated triglycerides, low HDL-C, or metabolic syndrome) is a candidate for TLC to modify these risk factors regardless of LDL-C level. Finally, for people in lower-risk categories, recent clinical trials do not modify the goals and cutpoints of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of combination fibrate–statin therapy in such patients is consistent with current guidelines that recommend treatment for patients with hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25”
From Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (2010) · cites this paper as [25]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to practice guidelines in place at the time of patient enrollment in IMPROVE-IT, treatment of hypercholesterolemia was based on lowering LDL cholesterol to target levels, 20,21 which were set on the basis of a patient's risk of cardiovascular events.”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [20]
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Statins are currently the most effective agents available for managing dyslipidemia and have been shown to reduce CV events in a wide variety of patient populations [10,25,31].”
In the citing paper
“Assiduous attention to abnormalities other than hyperglycemia that accompany type 2 diabetes, such as hypertension and dyslipidaemia, has been shown to improve microvascular and cardiovascular complications.”
From Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2009) · cites this paper as [21]
In the citing paper
“Nevertheless, measurement and treatment of blood lipids, blood pressure, and glucose levels have became the major emphases for cardiovascular risk reduction.”
From Beyond Established and Novel Risk Factors: Lifestyle Risk Factors for Cardiovascular Disease (2008) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Self-citationOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,060
Vascular Inflammation in Patients With Impaired Glucose Tolerance and Type 2 Diabetes
Kim, T. N., Kim, S., Yang, S. J., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2010) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.109.888909 · Cited by 115
Walmsley, S. L., Avihingsanon, A., Slim, J., Ward, D. J., Ruxrungtham, K., Brunetta, J. M., Bredeek, U. F., Jayaweera, D. T., Guittari, C. J., Larson, P., et al. (2009) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318198a815 · Cited by 115
Aberg, J. A., Zackin, R. A., Brobst, S. W., Evans, S. R., Alston, B., Henry, W. K., Glesby, M. J., Torriani, F. J., Yang, Y., Owens, S., et al. (2005) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2005.21.757 · Cited by 115
Pai, V., Paneerselvam, A., Mukhopadhyay, S., Bhansali, A. K., Kamath, D., Shankar, V., Gambhire, D., Jani, R. H., Joshi, S., & Patel, P. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296813518680 · Cited by 119
Ruel, G., Shi, Z., Zhen, S., Zuo, H., Kröger, E., Sirois, C., Lévesque, J., & Taylor, A. W. (2013) · Clinical Nutrition · doi:10.1016/j.clnu.2013.07.009 · Cited by 115
Kwak, H.-B., Thalacker-Mercer, A., Anderson, E. J., Lin, C.-T., Kane, D. A., Lee, N.-S., Cortright, R. N., Bamman, M. M., & Neufer, P. D. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.449 · Cited by 114
Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients
Kuhn, E. W., Liakopoulos, O. J., Stange, S., Deppe, A.-C., Slottosch, I., Choi, Y.-H., & Wahlers, T. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezt181 · Cited by 114
Pharmacological strategies for lowering LDL cholesterol: statins and beyond
Brautbar, A., & Ballantyne, C. M. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.2 · Cited by 115
Jellinger, P. S., Smith, D. A., Mehta, A., Ganda, O. P., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., Seibel, J. A., Kreisberg, R. A., & Goldberg, R. B. (2012) · Endocrine Practice · doi:10.4158/ep.18.2.269 · Cited by 113
Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients
Cham, S., Evans, M. A., Denenberg, J. O., & Golomb, B. A. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.541 · Cited by 114
Elens, L., Becker, M. L., Haufroid, V., Albert Hofman, D., Visser, L. E., Uitterlinden, A. G., Stricker, B. H. C., & van Schaik, R. H. N. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6edb · Cited by 114
Rosenson, R. S., Hislop, C., McConnell, D. S., Elliott, M., Stasiv, Y., Wang, N., & Waters, D. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60403-7 · Cited by 114
Carr, T. P., Weller, C. L., Schlegel, V. L., Cuppett, S. L., Guderian, D. M., & Johnson, K. R. (2005) · Journal of Nutrition · doi:10.1093/jn/135.9.2236 · Cited by 114
Effects of Niacin on Glucose Control in Patients With Dyslipidemia
Goldberg, R. B., & Jacobson, T. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.4.470 · Cited by 112
Lv, P., Zhou, M., He, J., Meng, W., Ma, X., Dong, S., Meng, X., Zhao, X. Y., Wang, X., & He, F. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15045774 · Cited by 116
Ku, C. S., Yang, Y. J., Park, Y., & Lee, J. (2013) · Journal of Medicinal Food · doi:10.1089/jmf.2012.2468 · Cited by 117
Wireless Non‐Invasive Monitoring of Cholesterol Using a Smart Contact Lens
Song, H., Shin, H., Seo, H., Park, W., Joo, B. J., Kim, J., Kim, J., Kim, H. K., Kim, J., & Park, J. (2022) · Advanced Science · doi:10.1002/advs.202203597 · Cited by 122
Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk
Ruggenenti, P. L., Cattaneo, D., Loriga, G., Ledda, F., Motterlini, N., Gherardi, G., Orisio, S., & Remuzzi, G. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.132522 · Cited by 114
Gaemperli, O., Bengel, F. M., & Kaufmann, P. A. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr057 · Cited by 112
Ballantyne, C. M., Bertolami, M. C., García, H. R. H., Nul, D. R., Stein, E. A., Théroux, P., Weiss, R., Cain, V. A., & Raichlen, J. S. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.12.013 · Cited by 112
Kreyenbuhl, J. A., Dickerson, F., Medoff, D. R., Brown, C. H., Goldberg, R. W., Fang, L., Wohlheiter, K. A., Mittal, L. P., & Dixon, L. B. (2006) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000221177.51089.7d · Cited by 109
A physiological characterization of the Cafeteria diet model of metabolic syndrome in the rat
Gomez-Smith, M., Karthikeyan, S., Jeffers, M. S., Janik, R., Thomason, L. A. M., Stefanovic, B., & Corbett, D. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.09.029 · Cited by 115
Duan, L.-P., Wang, H. H., Ōhashi, A., & Wang, D. Q. ‐. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00172.2005 · Cited by 111
Ahmed, S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl220 · Cited by 110
HDL-C: Role as a risk modifier
Barter, P. J. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70885-6 · Cited by 114
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
Telford, D. E., Sutherland, B. G., Edwards, J. Y., Andrews, J. D., Barrett, P. H. R., & Huff, M. W. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600439-jlr200 · Cited by 110
The impact of garlic on lipid parameters: a systematic review and meta-analysis
Reinhart, K. M., Talati, R., White, C. M., & Coleman, C. I. (2009) · Nutrition Research Reviews · doi:10.1017/s0954422409350003 · Cited by 110
Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., & Wu, X. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012502.pub2 · Cited by 109
Hong, M., Park, D., Lee, C.-W., Lee, S., Kim, Y., Kang, D., Song, J., Kim, J., Park, S., & Park, S.-J. (2009) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2009.03.015 · Cited by 107
Lifestyle‐Based Prediction Model for the Prevention of CVD: The Healthy Heart Score
Chiuve, S. E., Cook, N. R., Shay, C. M., Rexrode, K. M., Albert, C. M., Manson, J. E., Willett, W. C., & Rimm, E. B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000954 · Cited by 116
Bangalore, S., Fakheri, R. J., Toklu, B., Ogedegbe, G. G., WEINTRAUB, H. S., & Messerli, F. H. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.10.019 · Cited by 113
The Role of Lipids and Lipoproteins in Atherosclerosis
Linton, M. F., Yancey, P. G., Davies, S. S., Jerome, W. G., Linton, E. F., Song, W., Doran, A. C., & Vickers, K. C. (2015) · Europe PMC (PubMed Central) · Cited by 108
Metabolically Healthy Obesity—Heterogeneity in Definitions and Unconventional Factors
Brandão, I., Martins, M. J., & Monteiro, R. (2020) · Metabolites · doi:10.3390/metabo10020048 · Cited by 117
Han, E., Lee, Y., Kim, Y. D., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Lee, B., Kang, E. S., Soo, B., et al. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000572 · Cited by 109
Atorvastatin for lowering lipids
Adams, S. P., Tsang, M., & Wright, J. M. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008226.pub3 · Cited by 109
Overview of omega-3 Fatty Acid therapies.
Bradberry, J. C., & Hilleman, D. E. (2013) · PubMed Central · Cited by 109
The Influence of Graphic Format on Breast Cancer Risk Communication
Schapira, M. M., Nattinger, A. B., & McAuliffe, T. L. (2006) · Journal of Health Communication · doi:10.1080/10810730600829916 · Cited by 109
McMahon, M. A., Hahn, B. H., & Skaggs, B. J. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.10.98 · Cited by 115
A pulse-based diet is effective for reducing total and LDL-cholesterol in older adults
Abeysekara, S., Chilibeck, P. D., Vatanparast, H., & Zello, G. A. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000748 · Cited by 109
Lipoprotein(a), Hormone Replacement Therapy, and Risk of Future Cardiovascular Events
Danik, J. S., Rifai, N., Buring, J. E., & Ridker, P. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.009 · Cited by 111
Jenkins, D. J. A., Wong, J. M. W., Kendall, C. W. C., Esfahani, A., Ng, V. W. Y., Leong, T. C. K., Faulkner, D. A., Vidgen, E., Paul, G., Mukherjea, R., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-003505 · Cited by 109
Dichtl, W., Alber, H. F., Feuchtner, G. M., Hintringer, F., Reinthaler, M., Bartel, T., Süssenbacher, A., Grander, W., Ulmer, H., Pachinger, O., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.04.060 · Cited by 108
McCullough, P. A. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03871106 · Cited by 115
Williams, B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.069 · Cited by 108
(2004) · PubMed · Cited by 108
Kaddurah-Daouk, R. F., Baillie, R., Zhu, H., Zeng, Z., Wiest, M. M., Nguyen, U. T., Watkins, S. M., & Krauss, R. M. (2010) · Metabolomics · doi:10.1007/s11306-010-0207-x · Cited by 107
Novel metabolic biomarkers of cardiovascular disease
Jensen, M. K., Bertoia, M. L., Cahill, L. E., Agarwal, I., Rimm, E. B., & Mukamal, K. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.155 · Cited by 109
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary
Levine, G. N., Bates, E., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., Hollenberg, S. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.08.006 · Cited by 107
Catapano, A. L., Davidson, M. H., Ballantyne, C. M., Brady, W. E., Gazzara, R. A., Tomassini, J. E., & Tershakovec, A. M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132721 · Cited by 108
Bushnell, C., Culebras, A., DeGraba, T. J., Goldstein, B. A., Adams, R. J., Alberts, M. J., & Appel, L. J. (2006) · Cited by 108
Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe
Thompson, G. R., Catapano, A. L., Saheb, S., Atassi, M., Barbir, M., Eriksson, M., Paulweber, B., Sijbrands, E. J. G., Stalenhoef, A. F. H., & Parhofer, K. G. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283402f53 · Cited by 106
Valls, R. M., Farràs, M., Suárez, M., Fernández‐Castillejo, S., Fitó, M., Konstantinidou, V., Fuentes, F. J., López‐Miranda, J., Giralt, M., Covas, M., et al. (2014) · Food Chemistry · doi:10.1016/j.foodchem.2014.06.107 · Cited by 106
Bailey, K. M., Romaine, S. P. R., Jackson, B. M., Farrin, A. J., Efthymiou, M., Barth, J. H., Copeland, J., McCormack, T., Whitehead, A. L., Flather, M. D., et al. (2010) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.109.898502 · Cited by 106
Kulik, A., Voisine, P., Mathieu, P., Masters, R. G., Mesana, T. G., May, M. R. L., & Ruel, M. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.04.107 · Cited by 107
Awareness and Treatment of Dyslipidemia in Young Adults With Type 1 Diabetes
Wadwa, R. P., Kinney, G. L., Maahs, D. M., Snell‐Bergeon, J. K., Hokanson, J. E., Garg, S. K., Eckel, R. H., & Rewers, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1051 · Cited by 106
Lester, S. J., Eleid, M. F., Khandheria, B. K., & Hurst, R. T. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.3.229 · Cited by 106
Maki, K. C., Orloff, D. G., Nicholls, S. J., Dunbar, R. L., Roth, E. M., Curcio, D., Johnson, J., Kling, D., & Davidson, M. H. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.420 · Cited by 104
Jafri, H., Alsheikh-Ali, A. A. A., & Karas, R. H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00006 · Cited by 105
Kanaki, A., Sarafidis, P. A., Georgianos, P. I., Kanavos, K., Tziolas, I. M., Zebekakis, P. E., & Lasaridis, A. N. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hps098 · Cited by 105
Jensen, M. K., Aroner, S. A., Mukamal, K. J., Furtado, J. D., Post, W. S., Tsai, M. Y., Tjønneland, A. M., Polak, J. F., Rimm, E. B., Overvad, K., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.031276 · Cited by 109
Feringa, H. H. H., Karagiannis, S. E., van Waning, V. H., Boersma, E. H., Schouten, O., Bax, J. J., & Poldermans, D. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.01.024 · Cited by 106
Cardiovascular risk factors and cognitive function
Grodstein, F. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.01.001 · Cited by 106
Dall, T. M., Fulgoni, V. L. I., Zhang, Y., Reimers, K. J., Packard, P. T., & Astwood, J. D. (2009) · American Journal of Health Promotion · doi:10.4278/ajhp.080930-quan-226 · Cited by 102
Solà, R., Bruckert, É., Valls, R. M., Narejos, S., Luque, X., Cabezas, M. C., Doménech, G., Torres, F., Heras, M., Farrés, X., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.03.010 · Cited by 105
Intensive Multifactorial Intervention for Stable Coronary Artery Disease
Maron, D. J., Boden, W. E., O’Rourke, R. A., Hartigan, P. M., Calfas, K. J., Mancini, G. B. J., Spertus, J. A., Dada, M. R., Kostuk, W. J., Knudtson, M. L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.062 · Cited by 105
Chartoumpekis, D. V., & Kensler, T. W. (2013) · Current Diabetes Reviews · doi:10.2174/1573399811309020005 · Cited by 105
Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment
Gopal, K., Johnson, T. C., Gopal, S. K., Walfish, A., Bang, C. T., Suwandhi, P., Sahdala, H. N. P., Clain, D. J., Bodenheimer, H. C., & Min, A. D. (2006) · Hepatology · doi:10.1002/hep.21261 · Cited by 104
Statins for primary prevention of cardiovascular disease
Majeed, A. (2014) · BMJ · doi:10.1136/bmj.g3491 · Cited by 103
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy
Puri, R., Nissen, S. E., Shao, M., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., Libby, P., Raichlen, J. S., Uno, K., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht260 · Cited by 104
Recent Update to the US Cholesterol Treatment Guidelines
Nayor, M. G., & Vasan, R. S. (2016) · Circulation · doi:10.1161/circulationaha.116.021407 · Cited by 106
Stein, E. A., Ballantyne, C. M., Windler, E., Sirnes, P. A., Sussekov, A., Yigit, Z., Seper, C., & Gimpelewicz, C. R. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.09.099 · Cited by 102
Small LDL-Cholesterol is Superior to LDL-Cholesterol for Determining Severe Coronary Atherosclerosis
Koba, S., Yokota, Y., Hirano, T., Ito, Y., Ban, Y., Tsunoda, F., Sato, T., Shoji, M., Suzuki, H., Geshi, E., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e572 · Cited by 102
Glueck, C. J., Pandit, R., Kumar, A., Wang, P., Khayznikov, M., & Hemachrandra, K. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.153919 · Cited by 102
Association of Statin Use With Cataracts
Leuschen, J., Mortensen, E. M., Frei, C. R., Mansi, E. A., Panday, V. A., & Mansi, I. A. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.4575 · Cited by 102
Engaging Primary Care Patients to Use a Patient-Centered Personal Health Record
Krist, A. H., Woolf, S. H., Bello, G., Sabo, R. T., Longo, D. R., Kashiri, P. L., Etz, R., Loomis, J., Rothemich, S. F., Peele, J. E., et al. (2014) · The Annals of Family Medicine · doi:10.1370/afm.1691 · Cited by 102
Distribution of short and lifetime risks for cardiovascular disease in Italians
Castelnuovo, A. F. D., Costanzo, S., Persichillo, M., Olivieri, M., Curtis, A. D., Zito, F., Donati, M. B., de Gaetano, G., & Iacoviello, L. (2011) · European Journal of Preventive Cardiology · doi:10.1177/1741826711410820 · Cited by 102
Stroes, E. S. G., Guyton, J. R., Lepor, N. E., Civeira, F., Gaudet, D., Watts, G. F., Baccara‐Dinet, M. T., Lecorps, G., Manvelian, G. Z., Farnier, M., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003421 · Cited by 102
Ballantyne, C. M., Raichlen, J. S., & Cain, V. A. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.052 · Cited by 102
Miller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.046 · Cited by 102
Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis
Gleissner, C. A., Leitinger, N., & Ley, K. F. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.089854 · Cited by 103
on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1806-9 · Cited by 94
Ginsberg, H. N., Bonds, D. E., Lovato, L. C., Crouse, J. R., Elam, M. B., Linz, P. E., O’Connor, P. J., Leiter, L. A., Weiss, D., Lipkin, E., et al. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.024 · Cited by 95
Shepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 100
Oudkerk, M., Stillman, A. E., Halliburton, S. S., Kalender, W. A., Möhlenkamp, S., McCollough, C. H., Vliegenthart, R., Shaw, L. J., Stanford, W. L., Taylor, A. J., et al. (2008) · European Radiology · doi:10.1007/s00330-008-1095-6 · Cited by 100
Primary prevention of stroke: blood pressure, lipids, and heart failure
Endres, M., Heuschmann, P. U., Laufs, U., & Hakim, A. M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq472 · Cited by 107
Obesity and the metabolic syndrome in the elderly–a mini-review
Lechleitner, M. (2008) · Gerontology · doi:10.1159/000161734 · Cited by 100
Krantz, M. J., Coronel, S. M., Whitley, E. M., Dale, R., Yost, J., & Estacio, R. O. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301068 · Cited by 99
High prevalence of dyslipidemia and associated risk factors among rural Chinese adults
Sun, G., Li, Z., Guo, L., Zhou, Y., Yang, H., & Sun, Y. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-189 · Cited by 101
de Vries, F. M., Denig, P., Pouwels, K. B., Postma, M. J., & Hak, E. (2012) · Drugs · doi:10.2165/11638240-000000000-00000 · Cited by 99
Kasapis, C., & Gurm, H. S. (2009) · Current Cardiology Reviews · doi:10.2174/157340309789317823 · Cited by 102
Evidence Mandating Earlier and More Aggressive Treatment of Hypercholesterolemia
Steinberg, D. H., Glass, C. K., & Witztum, J. L. (2008) · Circulation · doi:10.1161/circulationaha.107.753152 · Cited by 102
Wiviott, S. D., de Lemos, J. A., Cannon, C. P., Blazing, M. A., Murphy, S. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.105.586347 · Cited by 97
Inclisiran: a new promising agent in the management of hypercholesterolemia
Kosmas, C. E., Muñoz Estrella, A., Sourlas, A., Silverio, D., Hilario, E., Montan, P. D., & Guzman, E. (2018) · Diseases · doi:10.3390/diseases6030063 · Cited by 99
Evidence‐based healthcare, clinical knowledge and the rise of personalised medicine
Miles, A., Loughlin, M., & Polychronis, A. (2008) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2008.01094.x · Cited by 99
Metabolomics Reveals Amino Acids Contribute to Variation in Response to Simvastatin Treatment
Trupp, M., Zhu, H., Wikoff, W. R., Baillie, R., Zeng, Z., Karp, P. D., Fiehn, O., Krauss, R. M., & Kaddurah‐Daouk, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038386 · Cited by 107
Acharjee, S., Boden, W. E., Hartigan, P. M., Teo, K. K., Maron, D. J., Sedlis, S. P., Kostuk, W. J., Spertus, J. A., Dada, M. R., CHAITMAN, B. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.051 · Cited by 100
Vemuri, K. V., Janero, D. R., & Makriyannis, A. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.012 · Cited by 103
Rosenson, R. S., Hislop, C., Elliott, M. D., Stasiv, Y., Goulder, M. A., & Waters, D. D. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.015 · Cited by 95
Vasudevan, A. R., & Balasubramanyam, A. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2004.6.850 · Cited by 101
Fierbinteanu-Braticevici, C. G., Sporea, I., Panaitescu, E., & Tribus, L. C. (2013) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2013.04.019 · Cited by 98
Metadata
- Authors
- Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J.
- Affiliations
- American College of Cardiology (US)
- Venue
- Circulation
- Published
- 2004-07-13
- Volume
- 110
- Issue
- 2
- Pages
- 227-239
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2106343349
- Cited by
- 6,902
- References
- 54
- Citations by year
- 2026: 32 · 2025: 44 · 2024: 72 · 2023: 71 · 2022: 85 · 2021: 100 · 2020: 127 · 2019: 137 · 2018: 152 · 2017: 189 · 2016: 248 · 2015: 324 · 2014: 382 · 2013: 506 · 2012: 489
- FWCI
- 539.21
- Type
- journal article
- Language
- en
- Update notices
- correction (2004-08-10)
- Open access
- bronze
- doi.org
- Locations
- Circulation (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- American Heart Association
- American College of Cardiology Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- Adult Treatment Panel III, LDL cholesterol targets, statin therapy, cholesterol-lowering therapy, diabetes mellitus, older adults, triglycerides, HDL cholesterol, nicotinic acid, therapeutic lifestyle changes, cardiovascular risk stratification, hypercholesterolemia, metabolic syndrome, cardiovascular disease prevention
- MeSH terms
- Aged, Anticholesteremic Agents, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Humans, Hypercholesterolemia, Hypertension, Cholesterol, LDL, Middle Aged, Myocardial Infarction, Patient Education as Topic, Risk, Risk Factors, Comorbidity, Thrombolytic Therapy, Randomized Controlled Trials as Topic, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
